Breast cancer risk in metabolically healthy but overweight postmenopausal women

Marc J. Gunter, Xianhong Xie, Xiaonan (Nan) Xue, Geoffrey C. Kabat, Thomas E. Rohan, Sylvia Wassertheil-Smoller, Gloria Y F Ho, Judith Wylie-Rosett, Theresa Greco, Herbert Yu, Jeannette Beasley, Howard Strickler

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Adiposity is an established risk factor for postmenopausal breast cancer. Recent data suggest that high insulin levels in overweight women may play a major role in this relationship, due to insulin's mitogenic/antiapoptotic activity. However, whether overweight women who are metabolically healthy (i.e., normal insulin sensitivity) have elevated risk of breast cancer is unknown. We investigated whether overweight women with normal insulin sensitivity [i.e., homeostasis model assessment of insulin resistance (HOMA-IR) index, or fasting insulin level, within the lowest quartile (q1)] have increased breast cancer risk. Subjects were incident breast cancer cases ( N = 497) and a subcohort ( N = 2,830) of Women's Health Initiative (WHI) participants with available fasting insulin and glucose levels. In multivariate Cox models, metabolically healthy overweight women, defined using HOMA-IR, were not at elevated risk of breast cancer compared with metabolically healthy normal weight women [HR HOMA-IR, 0.96; 95% confidence interval (CI), 0.64-1.42]. In contrast, the risk among women with high (q3-4) HOMA-IRs was elevated whether they were overweight (HRHOMA-IR, 1.76; 95% CI, 1.19-2.60) or normal weight ( HRHOMA-IR , 1.80; 95% CI, 0.88 - 3.70). Similarly, using fasting insulin to define metabolic health, metabolically unhealthy women (insulin q3-4) were at higher risk of breast cancer regardless of whether they were normal weight (HRinsulin, 2.06; 95% CI, 1.01-4.22) or overweight (HRinsulin, 2.01; 95% CI, 1.35- 2.99), whereas metabolically healthy overweight women did not have significantly increased risk of breast cancer (HRinsulin , 0.96; 95% CI, 0.64- 1.42) relative to metabolically healthy normal weight women. Metabolic health (e.g., HOMA-IR or fasting insulin) may be more biologically relevant and more useful for breast cancer risk stratification than adiposity per se .

Original languageEnglish (US)
Pages (from-to)270-274
Number of pages5
JournalCancer Research
Volume75
Issue number2
DOIs
StatePublished - Aug 8 2015

Fingerprint

Breast Neoplasms
Insulin Resistance
Confidence Intervals
Insulin
Fasting
Homeostasis
Weights and Measures
Adiposity
Health
Women's Health
Proportional Hazards Models
Glucose

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

Breast cancer risk in metabolically healthy but overweight postmenopausal women. / Gunter, Marc J.; Xie, Xianhong; Xue, Xiaonan (Nan); Kabat, Geoffrey C.; Rohan, Thomas E.; Wassertheil-Smoller, Sylvia; Ho, Gloria Y F; Wylie-Rosett, Judith; Greco, Theresa; Yu, Herbert; Beasley, Jeannette; Strickler, Howard.

In: Cancer Research, Vol. 75, No. 2, 08.08.2015, p. 270-274.

Research output: Contribution to journalArticle

Gunter, Marc J. ; Xie, Xianhong ; Xue, Xiaonan (Nan) ; Kabat, Geoffrey C. ; Rohan, Thomas E. ; Wassertheil-Smoller, Sylvia ; Ho, Gloria Y F ; Wylie-Rosett, Judith ; Greco, Theresa ; Yu, Herbert ; Beasley, Jeannette ; Strickler, Howard. / Breast cancer risk in metabolically healthy but overweight postmenopausal women. In: Cancer Research. 2015 ; Vol. 75, No. 2. pp. 270-274.
@article{0eb6ac43f7134be2bd215a117d0c6874,
title = "Breast cancer risk in metabolically healthy but overweight postmenopausal women",
abstract = "Adiposity is an established risk factor for postmenopausal breast cancer. Recent data suggest that high insulin levels in overweight women may play a major role in this relationship, due to insulin's mitogenic/antiapoptotic activity. However, whether overweight women who are metabolically healthy (i.e., normal insulin sensitivity) have elevated risk of breast cancer is unknown. We investigated whether overweight women with normal insulin sensitivity [i.e., homeostasis model assessment of insulin resistance (HOMA-IR) index, or fasting insulin level, within the lowest quartile (q1)] have increased breast cancer risk. Subjects were incident breast cancer cases ( N = 497) and a subcohort ( N = 2,830) of Women's Health Initiative (WHI) participants with available fasting insulin and glucose levels. In multivariate Cox models, metabolically healthy overweight women, defined using HOMA-IR, were not at elevated risk of breast cancer compared with metabolically healthy normal weight women [HR HOMA-IR, 0.96; 95{\%} confidence interval (CI), 0.64-1.42]. In contrast, the risk among women with high (q3-4) HOMA-IRs was elevated whether they were overweight (HRHOMA-IR, 1.76; 95{\%} CI, 1.19-2.60) or normal weight ( HRHOMA-IR , 1.80; 95{\%} CI, 0.88 - 3.70). Similarly, using fasting insulin to define metabolic health, metabolically unhealthy women (insulin q3-4) were at higher risk of breast cancer regardless of whether they were normal weight (HRinsulin, 2.06; 95{\%} CI, 1.01-4.22) or overweight (HRinsulin, 2.01; 95{\%} CI, 1.35- 2.99), whereas metabolically healthy overweight women did not have significantly increased risk of breast cancer (HRinsulin , 0.96; 95{\%} CI, 0.64- 1.42) relative to metabolically healthy normal weight women. Metabolic health (e.g., HOMA-IR or fasting insulin) may be more biologically relevant and more useful for breast cancer risk stratification than adiposity per se .",
author = "Gunter, {Marc J.} and Xianhong Xie and Xue, {Xiaonan (Nan)} and Kabat, {Geoffrey C.} and Rohan, {Thomas E.} and Sylvia Wassertheil-Smoller and Ho, {Gloria Y F} and Judith Wylie-Rosett and Theresa Greco and Herbert Yu and Jeannette Beasley and Howard Strickler",
year = "2015",
month = "8",
day = "8",
doi = "10.1158/0008-5472.CAN-14-2317",
language = "English (US)",
volume = "75",
pages = "270--274",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Breast cancer risk in metabolically healthy but overweight postmenopausal women

AU - Gunter, Marc J.

AU - Xie, Xianhong

AU - Xue, Xiaonan (Nan)

AU - Kabat, Geoffrey C.

AU - Rohan, Thomas E.

AU - Wassertheil-Smoller, Sylvia

AU - Ho, Gloria Y F

AU - Wylie-Rosett, Judith

AU - Greco, Theresa

AU - Yu, Herbert

AU - Beasley, Jeannette

AU - Strickler, Howard

PY - 2015/8/8

Y1 - 2015/8/8

N2 - Adiposity is an established risk factor for postmenopausal breast cancer. Recent data suggest that high insulin levels in overweight women may play a major role in this relationship, due to insulin's mitogenic/antiapoptotic activity. However, whether overweight women who are metabolically healthy (i.e., normal insulin sensitivity) have elevated risk of breast cancer is unknown. We investigated whether overweight women with normal insulin sensitivity [i.e., homeostasis model assessment of insulin resistance (HOMA-IR) index, or fasting insulin level, within the lowest quartile (q1)] have increased breast cancer risk. Subjects were incident breast cancer cases ( N = 497) and a subcohort ( N = 2,830) of Women's Health Initiative (WHI) participants with available fasting insulin and glucose levels. In multivariate Cox models, metabolically healthy overweight women, defined using HOMA-IR, were not at elevated risk of breast cancer compared with metabolically healthy normal weight women [HR HOMA-IR, 0.96; 95% confidence interval (CI), 0.64-1.42]. In contrast, the risk among women with high (q3-4) HOMA-IRs was elevated whether they were overweight (HRHOMA-IR, 1.76; 95% CI, 1.19-2.60) or normal weight ( HRHOMA-IR , 1.80; 95% CI, 0.88 - 3.70). Similarly, using fasting insulin to define metabolic health, metabolically unhealthy women (insulin q3-4) were at higher risk of breast cancer regardless of whether they were normal weight (HRinsulin, 2.06; 95% CI, 1.01-4.22) or overweight (HRinsulin, 2.01; 95% CI, 1.35- 2.99), whereas metabolically healthy overweight women did not have significantly increased risk of breast cancer (HRinsulin , 0.96; 95% CI, 0.64- 1.42) relative to metabolically healthy normal weight women. Metabolic health (e.g., HOMA-IR or fasting insulin) may be more biologically relevant and more useful for breast cancer risk stratification than adiposity per se .

AB - Adiposity is an established risk factor for postmenopausal breast cancer. Recent data suggest that high insulin levels in overweight women may play a major role in this relationship, due to insulin's mitogenic/antiapoptotic activity. However, whether overweight women who are metabolically healthy (i.e., normal insulin sensitivity) have elevated risk of breast cancer is unknown. We investigated whether overweight women with normal insulin sensitivity [i.e., homeostasis model assessment of insulin resistance (HOMA-IR) index, or fasting insulin level, within the lowest quartile (q1)] have increased breast cancer risk. Subjects were incident breast cancer cases ( N = 497) and a subcohort ( N = 2,830) of Women's Health Initiative (WHI) participants with available fasting insulin and glucose levels. In multivariate Cox models, metabolically healthy overweight women, defined using HOMA-IR, were not at elevated risk of breast cancer compared with metabolically healthy normal weight women [HR HOMA-IR, 0.96; 95% confidence interval (CI), 0.64-1.42]. In contrast, the risk among women with high (q3-4) HOMA-IRs was elevated whether they were overweight (HRHOMA-IR, 1.76; 95% CI, 1.19-2.60) or normal weight ( HRHOMA-IR , 1.80; 95% CI, 0.88 - 3.70). Similarly, using fasting insulin to define metabolic health, metabolically unhealthy women (insulin q3-4) were at higher risk of breast cancer regardless of whether they were normal weight (HRinsulin, 2.06; 95% CI, 1.01-4.22) or overweight (HRinsulin, 2.01; 95% CI, 1.35- 2.99), whereas metabolically healthy overweight women did not have significantly increased risk of breast cancer (HRinsulin , 0.96; 95% CI, 0.64- 1.42) relative to metabolically healthy normal weight women. Metabolic health (e.g., HOMA-IR or fasting insulin) may be more biologically relevant and more useful for breast cancer risk stratification than adiposity per se .

UR - http://www.scopus.com/inward/record.url?scp=84920971232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920971232&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-14-2317

DO - 10.1158/0008-5472.CAN-14-2317

M3 - Article

C2 - 25593034

AN - SCOPUS:84920971232

VL - 75

SP - 270

EP - 274

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 2

ER -